Skip to main content
Equibles
ALKS logo

ALKS · Alkermes plc.

Track ALKS — free

Use ALKS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ALKS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$49.06 -0.39 (-0.79%) At close · Aug 14
Market Cap
$8.23B
Shares
167.76M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$49.06 Open$49.37 Day$48.65–50.02 52W close$26.52–55.22 Avg vol 30d1.7M Short int14.4M · 8.6% float · 7.7d Short vol55% Last earningsJul 28, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 28

Up next

Next earnings call
Oct 21, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 28, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Moderate
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +35%
      above
      Price vs 50-day avg −1%
      below
      RSI (14) 46
      neutral
      MACD trend Negative
      52-week position 79%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return −7%
      trailing
      6-month return +52%
      trailing
      YTD return +75%
      this year
      Relative strength +39%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $50 › 200d $36 — 50d above 200d
      Institutional flow Accumulating
      +6% holders QoQ · +91 funds added
      Insider flow Distributing
      Net -$2.9M over 90 days · 100% sells
      Short interest Falling
      8.59% of float · ▼ -4.1% MoM · 7.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      416 holders — near 3-yr high, broad support
      Squeeze score 68
      elevated · 0–100
      Fundamentals
      Fair
      Revenue growth −5%
      Y/Y
      EPS growth −34%
      Y/Y
      Free cash flow $480.3M
      Valuation P/E 129.1
      rich
      Buyback $172.3M
      remaining
      Balance sheet $388.6M
      net cash
      Quant / Vol
      risk profile
      Moderate
      Volatility 41%
      annualized · 1-yr
      Max drawdown −22%
      past year
      ATR 3.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 28, 2026
      2026 Expectations
      Total Revenues $1.73B – $1.84B
      VIVITROL Net Sales $460M – $480M
      ARISTADA Net Sales $365M – $385M
      LYBALVI Net Sales $380M – $400M
      Cost of Goods Sold $320M – $340M
      R&D Expenses $445M – $485M
      SG&A Expenses $890M – $930M
      Amortization of Intangible Assets $75M – $85M
      Change in the Fair Value of Contingent Consideration $25M
      Net Tax Benefit $0
      Net Interest Expense $75M – $85M
      GAAP Net Loss $-115M – $-95M
      EBITDA $75M – $95M
      Adjusted EBITDA $370M – $410M
      Feb. 12, 2026 – Dec. 31, 2026
      LUMRYZ Net Sales $315M – $335M
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
      Total revenues · 2025 full-year $1.43B – $1.49B
      GAAP net income · 2025 full-year $230M – $250M
      EBITDA · 2025 full-year $270M – $290M
      Adjusted EBITDA · 2025 full-year $365M – $385M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 5 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +35% Bullish
      Price vs 50-day avg
      −1% Neutral
      RSI (14)
      46 Neutral
      MACD trend
      Negative Bearish
      52-week position
      79% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $50 › 200d $36 — 50d above 200d
      Institutional flow Accumulating
      +6% holders QoQ · +91 funds added
      Insider flow Distributing
      Net -$2.9M over 90 days · 100% sells
      Short interest Falling
      8.59% of float · ▼ -4.1% MoM · 7.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      416 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $27 Now $49 · 79% Range high $55
      vs 200-day avg +35% vs 50-day avg -1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP Net (Loss) Income — GAAP -65.98M
      -13.88M Interest income
      +46.82M Interest expense
      +2.18M Income tax provision
      +15.45M Depreciation expense
      +34.26M Amortization of acquired intangible assets
      +85.88M Share-based compensation
      +88.35M Costs related to the acquisition of Avadel
      +26.41M Change in the fair value of contingent consideration
      = Adjusted EBITDA 219.48M
      EBITDA $285.6M Twelve Months Ended December 31, 2025 —
      GAAP → non-GAAP reconciliation
      GAAP Net Income from Continuing Operations 241.66M
      +27.09M Depreciation expense
      +75K Amortization expense
      -45.3M Interest income
      +12.28M Interest expense
      +49.79M Income tax provision
      = EBITDA 285.59M
      EBITDA From Continuing Operations $285.6M Twelve Months Ended December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ALKS
      Alkermes plc.
      this stock
      		$8.23B +75.3% -5.2% 129.1 8.6%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $64.91B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $56.30B +13.1% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $49.59B +2.4% — — 0.0%
      TEVA
      Teva Pharmaceutical Industries Ltd
      		 $42.85B +17.8% +4.3% 60.3 2.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      416
      % held
      106.7%
      Net QoQ
      +2.2M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      159
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      14.4M
      Days to cover
      7.7d
      Change
      -610.8K sh
      View
      Short Volume
      Short vol %
      55%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      229.4K
      Value
      $12.0M
      As of
      Jul 1, 2026
      View
      Off-Exchange
      Off-exchange %
      37.5%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$2.9M
      Buyers / Sellers
      0 / 2
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $1.5B
      Net income (FY)
      $241.7M
      EPS diluted
      $1.43
      View
      Buybacks
      Authorized
      $400.0M
      Remaining
      $172.3M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 12, 2026
      This year
      19
      View
      Proposed Sales
      Value
      $2.2M
      Shares
      44.5K
      Filed
      Aug 3, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 28, 2026
      View
      Investor Relations
      Latest news
      Alkermes plc Reports Second Quart…
      Published
      Jul 28, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ALKS -0.2% -6.9% +52.4% +0.1% +75.3%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY -0.6% -11.4% +38.6% -3.8% +61.5%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $400.00M
      Spent (derived)
      $227.70M
      Remaining
      $172.30M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1520262 CUSIP G01767105 13F (30d) 407 filings 389 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)